Key result
CaMKII inhibition emerges as a potential therapy to prevent cardiac dysfunction and arrhythmias in diabetic cardiomyopathy.
Why the study?
Diabetic patients still experience a significantly greater burden of cardiac pathology despite current therapies, creating a great need for novel therapeutic approaches such as CaMKII inhibition.
Does CaMKII inhibition prevent diabetic cardiomyopathy in the setting of diabetes?
Does CaMKII inhibition prevent diabetic cardiomyopathy in the setting of diabetes?
CaMKII inhibition represents a promising novel therapeutic target for the prevention and treatment of diabetic cardiomyopathy.
Should not yet change diabetic cardiomyopathy management; leaves open CaMKII inhibition as a hypothesis-generating target.
Increasing prevalence of diabetes mellitus worldwide has pushed the complex disease state to the foreground of biomedical research, especially concerning its multifaceted impacts on the cardiovascular system. Current therapies for diabetic cardiomyopathy have had a positive impact, but with diabetic patients still suffering from a significantly greater burden of cardiac pathology compared to the general population, the need for novel therapeutic approaches is great. A new therapeutic target, calcium/calmodulin-dependent kinase II (CaMKII), has emerged as a potential treatment option for preventing cardiac dysfunction in the setting of diabetes. Within the last 10 years, new evidence has emerged describing the pathophysiological consequences of CaMKII activation in the diabetic heart, the mechanisms that underlie persistent CaMKII activation, and the protective effects of CaMKII inhibition to prevent diabetic cardiomyopathy. This review will examine recent evidence tying cardiac dysfunction in diabetes to CaMKII activation. It will then discuss the current understanding of the mechanisms by which CaMKII activity is enhanced during diabetes. Finally, it will examine the benefits of CaMKII inhibition to treat diabetic cardiomyopathy, including contractile dysfunction, heart failure with preserved ejection fraction, and arrhythmogenesis. We intend this review to serve as a critical examination of CaMKII inhibition as a therapeutic strategy, including potential drawbacks of this approach.
No takes yet. Share an insight, caveat, or question.
Veitch et al. (2021) conducted a review in Diabetic Cardiomyopathy. CaMKII inhibition was evaluated. CaMKII inhibition emerges as a potential therapeutic strategy to prevent cardiac dysfunction, contractile abnormalities, and arrhythmogenesis in the setting of diabetic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: